Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 51.7% in March

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 908 shares, a decrease of 51.7% from the February 26th total of 1,878 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 16,950 shares, the days-to-cover ratio is currently 0.1 days.

Bolt Biotherapeutics Trading Up 4.9%

Shares of Bolt Biotherapeutics stock opened at $4.50 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.59 and a current ratio of 3.59. The firm has a 50-day moving average of $5.17 and a 200-day moving average of $5.32. Bolt Biotherapeutics has a 52-week low of $3.91 and a 52-week high of $9.38. The stock has a market cap of $8.64 million, a PE ratio of -0.25 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Thursday, March 12th. The company reported ($3.84) EPS for the quarter, topping analysts’ consensus estimates of ($4.27) by $0.43. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $0.67 million. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%. As a group, sell-side analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Analyst Upgrades and Downgrades

BOLT has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $34.00.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BOLT. Squarepoint Ops LLC lifted its stake in Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics in the 3rd quarter valued at $85,000. Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth $89,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics during the 4th quarter worth $112,000. Finally, Renaissance Technologies LLC lifted its position in shares of Bolt Biotherapeutics by 92.2% during the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares during the last quarter. 86.70% of the stock is currently owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.